141 results
Page 3 of 8
424B5
8n5wo4u3oj0yf3cpoq
19 Mar 10
Prospectus supplement for primary offering
12:00am
424B5
7qj 0y1av
17 Mar 10
Prospectus supplement for primary offering
12:00am
8-K
EX-99.1
kq0huoojyws
20 Jan 10
Regulation FD Disclosure
12:00am
8-K
EX-99.1
urqium69zsts
14 Jan 10
Regulation FD Disclosure
12:00am
S-3
nfpngrcaebad9rvhxvp3
23 Jul 09
Shelf registration
12:00am
8-K
EX-99
9nt2dhd0jbw4dxxnqwfz
23 Jul 09
Results of Operations and Financial Condition
12:00am
8-K
EX-99
lmzpky79ll
24 Apr 09
Regulation FD Disclosure
12:00am
8-K
EX-99
ta9rvtv
22 Apr 09
Results of Operations and Financial Condition
12:00am
8-K
EX-99
5zzrcrpjef
6 Apr 09
Regulation FD Disclosure
12:00am
8-K
EX-99
r3orp
26 Feb 09
Regulation FD Disclosure
12:00am
8-K
EX-99
z9xrqxiwu elk
12 Feb 09
Results of Operations and Financial Condition
12:00am
8-K
EX-99.1
llkufh6cx9j48sh0hpvm
4 Feb 09
GSK and Theravance announce positive phase 2b results for once-daily fluticasone furoate in the treatment of asthma
12:00am
8-K
EX-99
lpwyhxiaf ad
26 Jan 09
Regulation FD Disclosure
12:00am
8-K
EX-99.1
73m7qtcu 73zinvq2bd
22 Dec 08
GSK and Theravance Announce Positive Phase 2b Results for LABA ‘444 in the Treatment of COPD in the Horizon Development Programme
12:00am
8-K
EX-99.1
ldzyi8tqwdlqgtm28x42
2 Dec 08
Initial results demonstrate potential of ‘444 in the treatment of patients with moderate to severe asthma
12:00am